A second round of funding has been secured for a Liverpool company whose technology could revolutionise the self-test diagnostics market
Platform Diagnostics is pioneering a new method of diagnostic test that gives an accurate digital reading and can be used anywhere.
The investment from the RisingStars Growth Fund and the North West Equity Fund will enable the company to complete development of the technology in its MerseyBio incubator facility and to bring the first test to market by 2005.
A disposable digital pregnancy test has demonstrated proof of concept and secured licensing and manufacturing agreements with a large US company.
The company is now developing the technology for use in tests where quantitative results are required.
The technology, which will be licensed, infringes no patents and the test kits will be economic to manufacture and reliable in use.
Platform Diagnostics is actively looking to collaborate with diagnostics companies interested in using the platform technology to help them develop quantitative tests within their individual areas of expertise.
